Ciprandi, G.; Varriccchio, A. Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections. Children2023, 10, 1210.
Ciprandi, G.; Varriccchio, A. Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections. Children 2023, 10, 1210.
Ciprandi, G.; Varriccchio, A. Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections. Children2023, 10, 1210.
Ciprandi, G.; Varriccchio, A. Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections. Children 2023, 10, 1210.
Abstract
Respiratory infections are usually characterized by mucus hypersecretion. This condition may worsen and prolong symptoms and signs. Mucoactive agents include different molecules with different mechanisms of action. Sobrerol is a monoterpene able to fluidify mucus, increase mucociliary clearance, and exert antioxidant activity. Sobrerol is available in various formulations (granules, syrup, nebulized, and suppository). Sobrerol has been on the market for over 50 years. Several studies investigated its efficacy and safety in acute and chronic respiratory diseases characterized by mucus hyperproduction. Seven pediatric studies have been conducted with favorable outcomes. Recently, regulatory agencies reduced the treatment duration to three days. Therefore, a future study will test the hypothesis that a combination of oral and topical sobrerol could benefit children and adults with frequent respiratory infections. The rationale considers that mucus accumulation could be a risk factor for increased susceptibility to have infections.
Keywords
sobrerol; mucolytic agent; respiratory infections
Subject
Medicine and Pharmacology, Otolaryngology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
